News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lightlake Therapeutics Inc. (LLTP)’ Binge Eating Disorder Treatment Phase II Trial Results Presented at American Psychiatric Association 2013 Annual Meeting


5/23/2013 8:07:09 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Lightlake Therapeutics Inc. (OTCBB: LLTP) (the “Company”, “We” or “Lightlake”), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company’s Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder (“BED”) were presented at the American Psychiatric Association (“APA”) Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES